
Isomorphic Laboratories applies advanced AI to accelerate and improve drug discovery, enabling researchers to design molecules and predict their performance earlier in development. The company builds on AlphaFold and deep learning models to model biological systems, generate candidate therapeutics, and simulate compound behavior. It operates as an AI-first drug discovery platform focused on strategic research collaborations with pharmaceutical companies, biotech firms, and CROs. Core technologies include machine learning, deep learning, and AlphaFold-derived protein-structure modeling. Isomorphic targets the biopharma market to shorten discovery timelines and increase predictive accuracy for therapeutic development.

Isomorphic Laboratories applies advanced AI to accelerate and improve drug discovery, enabling researchers to design molecules and predict their performance earlier in development. The company builds on AlphaFold and deep learning models to model biological systems, generate candidate therapeutics, and simulate compound behavior. It operates as an AI-first drug discovery platform focused on strategic research collaborations with pharmaceutical companies, biotech firms, and CROs. Core technologies include machine learning, deep learning, and AlphaFold-derived protein-structure modeling. Isomorphic targets the biopharma market to shorten discovery timelines and increase predictive accuracy for therapeutic development.
Core proposition: AI-first drug discovery platform building on AlphaFold to design and simulate therapeutic candidates
Founded: 2021
Headquarters: King's Cross, London
Notable founder/CEO: Sir Demis Hassabis
Recent funding: $600M external round (Mar 31, 2025) led by Thrive Capital
| Company |
|---|
Drug discovery and early-stage therapeutic design
2021
Biotechnology Research
$600,000,000
First external funding round; participation from GV and follow-on capital from Alphabet
“Led by Thrive Capital with participation from GV and follow-on capital from Alphabet”
Isomorphic Labs (IsoLabs) was founded in 2021 and is led by Sir Demis Hassabis. Our aim is to usher in a new era of biomedical breakthroughs and find cures for some of humanity’s devastating diseases.
Our foundations are built on the success of Google DeepMind’s AlphaFold, and we are continuing to develop and implement state-of-the-art technologies to dramatically accelerate and improve the process of designing and bringing new medicines to patients.
We have built a world-leading drug design engine comprising foundational AI models capable of working across multiple therapeutic areas and drug modalities. The company continually innovates on model architecture and develops cutting-edge capabilities to advance rational drug design.
Job Title: InfoSec Risk and Governance Lead
Location: London, England, United Kingdom
Employment Type: Full-time
Department: Information Security
As the Information Security Risk and Governance Lead, you will:
Essential:
Nice to Have:
We follow a hybrid model, requiring in-office presence 3 days a week (currently Tuesday, Wednesday, and one other day). We are open to discussing accommodations for those with additional needs.